Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Oral QPX7831 in Healthy Adult Subjects

This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult subjects.

Study Overview

• Status: Completed
• Conditions: Bacterial Infections
• Intervention / Treatment: Drug: QPX7831; Drug: placebo comparator

Detailed Description

Qpex Biopharma, Inc. is developing an oral dosage form that delivers QPX7728, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases, for oral treatment in combination with a beta-lactam antibiotic.

The objectives are:

1. To assess the safety and tolerability of QPX7831 when administered orally in single ascending doses (SAD) and in multiple ascending doses (MAD) to healthy adult subjects.
2. To assess the PK of single and multiple doses of oral QPX7831 when administered to healthy adult subjects to determine if the target exposures identified in preclinical studies can be attained in healthy adult subjects.

• Study Type: Interventional
• Enrollment (Actual): 75
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • South Australia
    • Adelaide, South Australia, Australia
      • CMAX
• United States
  • California
    • Cypress, California, United States, 90630
      • Altasciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy adult males and/or females of non-childbearing potential, 18 to 55 years of age (inclusive) at the time of screening.
2. Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive).
3. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, electrocardiograms [ECGs], physical examination) as assessed by the PI.
4. Voluntarily consent to participate in the study.

5. Male volunteers must agree to use a condom when engaging in any sexual activity from study check-in through 30 days following the last administration of the study drug, and to not donate sperm during this same period of time. If engaging in sexual activity with a female partner of childbearing potential, an additional method of birth control must be used. Approved additional methods of birth control include:

   1. Intra-uterine device (IUD) in place for at least 3 months prior to Day 1 through 30 days following the final dosing of the study drug.
   2. Barrier method (diaphragm) for at least 14 days prior to Day 1 through 30 days following dosing of the study drug.
   3. Stable hormonal contraceptive for at least 3 months prior to Day 1 through 30 days following dosing of the study drug.
   4. Surgical sterilization (vasectomy) at least 6 months prior to Day 1.

6. Females of non-childbearing potential with serum FSH levels ≥ 40 mIU/mL are either postmenopausal (defined as 12 months spontaneous amenorrhea) or have undergone one of the following sterilization procedures at least 6 months prior to Day 1 (and is documented):

   1. Bilateral tubal ligation;
   2. Hysterectomy;
   3. Hysterectomy with unilateral or bilateral oophorectomy;
   4. Bilateral oophorectomy.

Exclusion Criteria:

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
2. Positive urine drug/alcohol testing at screening or check-in (Day -1).
3. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
4. History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.
5. Use of more than 5 packs/week of cigarettes (or equivalent amount of nicotine-containing product) within 6 months prior to Day 1. Subjects must agree to refrain from smoking for the duration of the study.
6. Excessive intake of alcohol, defined as an average daily intake of greater than 2 standard drinks for women and 4 standard drinks for men; 1 bottle of beer (375mL) is equivalent to approximately 1.4 standard drinks, 1 glass of spirits (30mL) is equivalent to approximately 1 standard drink and 1 glass (150mL) of wine is equivalent to approximately 1.5 standard drinks.
7. Use of any prescription medication (with the exception of hormone replacement therapy for females) within 14 days prior to Day 1.
8. Use of any over the counter (OTC) medication, including herbal products, probiotics and vitamins, within the 7 days prior to Day 1. Up to 2 grams per day of paracetamol is allowed for acute events at the discretion of the PI.
9. Use of antacids, H2 receptor blockers or proton pump inhibitors within 7 days prior to Day 1.
10. Documented hypersensitivity reaction or anaphylaxis to any medication
11. Blood donation or significant blood loss (i.e., > 500 mL) within 56 days prior to Day
12. Plasma donation within 7 days prior to Day 1.
13. Participation in another investigational clinical trial within 30 days prior to Day 1 or within 5 half-lives of the previous investigational drug, whichever is longer.
14. Females who are pregnant or lactating.
15. Surgery within the past three months prior to Day 1 determined by the PI to be clinically relevant.
16. Any acute illness within 30 days prior to Day 1.
17. QTcF interval >450 msec for males and >470 for females or history of prolonged QT syndrome at screening or check-in (Day -1).
18. Calculated creatinine clearance less than 80 mL/min (Cockcroft-Gault method) at screening or check-in (Day -1).

19. Subjects who have any clinically significant abnormalities on laboratory values at screening or check-in (Day -1), in particular:

    1. White blood cell count < 3,000/mm3, hemoglobin < 11g/dL.
    2. Absolute neutrophil count < 1,200/mm3 or platelet count < 120,000/mm3.
    3. Liver function abnormalities at screening or check-in (Day -1) (defined by an elevation in bilirubin, AST or ALT 1.5 x ULN of the normal range for subjects based on age and sex).
20. Any other condition or prior therapy, which, in the opinion of the PI, would make the subject unsuitable for this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: QPX7831 SAD Cohorts; oral, single ascending dose (or placebo)	Drug: QPX7831; capsule; Drug: placebo comparator; oral matched placebo capsule
Experimental: QPX7831 MAD Cohorts; oral, multiple ascending dose (or placebo)	Drug: QPX7831; capsule; Drug: placebo comparator; oral matched placebo capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment -Emergent Adverse events by subject and by cohort (single dose, multiple doses)	Number of patients with Treatment-Emergent AEs by subject, by cohort, severity and relationship to treatment	up to 17 days
Number of patients with changes from baseline in safety parameters	Number of patients with changes in safety parameters before and after dosing by subject and cohort	up to 17 days
Peak plasma Concentration measurements by subject and by cohort (Cmax)	Comparison will be performed between the cohorts for Cmax. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.	up to 17 days
Time concentration data measurements by subject and by cohort (Tmax)	Comparison will be performed between the cohorts for Tmax.	up to 17 days
Area under the plasma concentration versus time curve (AUC) between cohorts	Comparison will be performed between the cohorts for AUC. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.	up to 17 days
Urine PK amount excreted by subject and by cohort	Urine PK parameters such as amount excreted will be calculated from urinary excretion data	up to 17 days
Urine PK % dose excreted by subject and by cohort	Urine PK parameters such as amount of % dose excreted will be calculated from urinary excretion data	up to 17 days

Collaborators and Investigators

• Sponsor: Qpex Biopharma, Inc.
• Collaborators: Biomedical Advanced Research and Development Authority
• Investigators: Study Director: Jeffery Loutit, MBChB, Qpex Biopharma, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): April 13, 2021
• Primary Completion (Actual): August 30, 2022
• Study Completion (Actual): August 30, 2022

Study Registration Dates

• First Submitted: September 29, 2020
• First Submitted That Met QC Criteria: October 1, 2020
• First Posted (Actual): October 8, 2020

Study Record Updates

• Last Update Posted (Actual): October 10, 2022
• Last Update Submitted That Met QC Criteria: October 6, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: beta-lactamase inhibitor
• Additional Relevant MeSH Terms: Infections; Bacterial Infections and Mycoses; Bacterial Infections
• Other Study ID Numbers: Qpex-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No